EUVIMEDEUVIMED entdecken
Open Access

Market dynamics of authorized generics in Medicaid from 2014 to 2020

Benjamin N Rome iD, Simon J Gunter, Aaron S Kesselheim

Health Services Research · 2023

DOI: 10.1111/1475-6773.14145 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Services Research, 2023. Verfasst von Benjamin N Rome und 2 weiteren Autor:innen. Beteiligte Einrichtung: Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Wo…. Hauptthemen laut MEDLINE: Medicaid, Prescription Drugs. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the use and timing of market introduction of authorized generics (AGs), which unlike independent generics are sold by the brand‐name drug manufacturer under a generic label. Data Sources This study used public Medicaid prescription drug use data from 2014 to 2020. Study Design This cross‐sectional study measured the percentage of filled prescriptions for AGs, compared with brand‐name and independent generic versions. We also identified the frequency and characteristics of AGs marketed at least 1 year before independent generics. Data Extraction Methods Drugs were classified based on manufacturer‐reported data to Medicaid. Principal Findings From 2014 to 2020, 1023 AGs accounted for 175 million filled Medicaid prescriptions. These represented 4% of Medicaid prescription drug use, and 16% of medication use among products with AGs available. Among 393 AGs for drugs without generic competition before 2014, 139 (35%) were marketed at least 1 year before independent generics or had no independent generic competition through December 2020.

Conclusions

AGs represented a small share of Medicaid prescription drug use from 2014 to 2020, but when AGs were available, they accounted for sizeable market share. Among the minority of cases in which AGs were marketed a year or more before independent generics, manufacturers may be using AGs to bolster brand‐name drug prices or to undermine independent generic competition, meriting further attention by regulators.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MedicaidPrescription DrugsUnited StatesHumansCross-Sectional StudiesDrug Costs

Stichwörter der Autor:innen

Medicaidauthorized genericsgeneric drugshealth policyprescription drugs

Substanzen

Prescription Drugs

Autor:innen und Institutionen

  • Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Benjamin N Rome

Zitieren

APA

Rome, B. N., Gunter, S. J., & Kesselheim, A. S. (2023). Market dynamics of authorized generics in Medicaid from 2014 to 2020. Health Services Research. https://doi.org/10.1111/1475-6773.14145

Vancouver

Rome BN, Gunter SJ, Kesselheim AS. Market dynamics of authorized generics in Medicaid from 2014 to 2020. Health Services Research. 2023. doi:10.1111/1475-6773.14145

BibTeX
@article{Rome2023,
  author = {Rome, Benjamin N and Gunter, Simon J and Kesselheim, Aaron S},
  title = {Market dynamics of authorized generics in Medicaid from 2014 to 2020},
  journal = {Health Services Research},
  year = {2023},
  doi = {10.1111/1475-6773.14145}
}
Kostenlos starten →